Clinical Study of Concurrent Chemoradiotherapy with Anlotinib Combined with Sintilimab in the Treatment of Driver-Gene Negative Non-Small Cell Lung Cancer
Objective To investigate the efficacy and safety of first-line concurrent chemoradiotherapy with anlotinib combined with sintilimab in the treatment of driver-gene negative non-small cell lung cancer(NSCLC).Methods A total of 80 patients with driver-gene negative NSCLC admitted to the Zhangjiagang Hospital Affiliated to Soochow University from March 2021 to March 2022 were selected and divided into two groups by the random number table method,with 40 cases in each group.The patients in the control group received NP chemotherapy regimen(30 mg/m2 of cisplatin + 25 mg/m2 of vinorelbine)and radiation therapy for primary lung lesions and regional lymph nodes.On this basis,the patients in the observation group received anlotinib + 200 mg/m2 of sintilimab on the first day.Both groups were treated four cycles of treatment with 21 d as a cycle.Results The objective response rate(ORR)and disease control rate(DCR)in the observation group were 72.50%and 85.00%,which were significantly higher than 37.50%and 52.50%in the control group(P<0.05).After treatment,the levels of serum carcinoembryonic antigen(CEA),carbohydrate antigen 125(CA125),and cytokeratin 19 fragment antigen 21-1(CYFRA21-1)in the two groups significantly reduced(P<0.05),while the scores of the Quality of Life Core Questionnaire(QLQ-C30)and the Quality of Life Questionnaire-Lung Cancer Module(QLQ-LC13)significantly increased(P<0.05),and those in the observation group were significantly better than those in the control group(P<0.05).The incidence of grade Ⅲ and above adverse reactions in the observation group was comparable to that in the control group(62.50%vs.52.50%,P>0.05).The median follow-up time for all patients was 15 months(12-24 months),with three cases lost to follow-up.The median progression-free survival(PFS)and median overall survival(OS)in the observation group were 6.9 months and 12.6 months,which were significantly longer than 4.3 months and 8.9 months in the control group(Log-rank χ2 = 13.760,31.830,P<0.05).Conclusion Concurrent chemoradiotherapy with anlotinib combined with sintilimab in the treatment of patients with driver-gene negative NSCLC can improve the clinical efficacy,improve the quality of life,reduce serum tumor marker levels,prolong survival time,and have high safety.
万方数据
维普
